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Introduction 
 
Investment in pharmaceutical research and development (R&D) 
has increased substantially in the last decades. Disappointingly, this 
has not translated into a corresponding increase in output in terms of 
new drugs approved, indicating that therapeutic innovation has 
become more challenging [1]. At the same time healthcare costs are 
steadily spiralling, fuelled by the ageing of the population and the 
parallel rise in the chronic disease burden. European healthcare 
systems are therefore faced with the challenge of delivering optimal 
treatment, with both improved outcomes and reductions in costs, to 
needy patient populations [2, 3].  
Late stage drug development is the most costly area of drug R&D 
and also shows the highest attrition rate [4], with severe financial 
implications. Achieving a decrease in late-stage drug failure will 
require the optimisation of the drug discovery phase to increase both 
the probability of success and the number of New Chemical Entities 
(NCE) in pharmaceutical pipelines [5]. Drug discovery programmes 
are initiated and driven by the belief that an efficacious new drug can 
be identified and made available to suffering human patients. 
Nevertheless, even if a drug lead is identified, the path to clinical drug 
candidate is the most idiosyncratic segment of drug discovery and 
development, with frequent setbacks and failures which defy 
generalisation [6].  
 
Novel collaborative models are needed for pharmaceutical 
R&D 
 
Many pharmaceutical companies are realising that a paradigm 
shift in the industry’s research and development (R&D) strategy is the 
only way of reversing the currently  ongoing  negative  trend.  Novel  
  
 
 
 
 
 
 
 
 
strategies based on an integrated and collaborative approach are 
required, building on innovation and leveraging on the strengths and 
input of all stakeholders in the health system with the shared goal of 
delivering effective and sustainable healthcare solutions for society [7, 
8].  
One approach that has gained momentum in recent years is the 
establishment of precompetitive public–private partnerships (PPPs), 
as ideal vehicles to solve issues that are too large for single 
organisations to effectively address alone. Such models rely on open 
innovation networks that link up the know-how and resources of the 
pharmaceutical industry with external pools of knowledge, especially 
in universities and biotechnology companies [9,10].  
This concept has been pioneered in the area of neglected diseases 
(e.g. see http://www.mmv.org/about-us) where public private 
partnerships have been vital to fill the development pipeline [11]. In 
the last years several PPPs in the pharmaceutical sector have been 
launched [12,13]. In particular, in the USA PPPs have been fostered 
by the US Food and Drug Administration, under the umbrella of the 
Critical Path Initiative [14], and by the National Institutes of Health 
(NIH) [9,15]. In Europe, the Innovative Medicines Initiative (IMI), a 
public-private partnership between the EU and the European 
Federation of Pharmaceutical Industries and Associations, is a 
prototypic example of an organisation created to support open 
innovation and pre-competitive research in the pharmaceutical sector 
[16]. IMI-sponsored activities are conducted by consortia that bring 
together pharmaceutical companies, small- and medium-sized 
enterprises (SMEs) and partners from the public sector. EFPIA-
affiliated pharmaceutical companies invest in the form of ‘in kind’ 
contributions by committing resources, providing access to data sets 
and infrastructures, and sometimes through direct monetary 
contributions. At least two companies actively participate in each 
project. This industry investment is matched by funds from the 
European Commission’s Seventh Framework Programme for 
Research and Technological Development (FP7) to other consortium 
members, including academic teams, SMEs, patients’ organisations, 
regulatory agencies and other non-profit institutions.  
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IMI contribution to ease the bottlenecks of drug discovery 
 
The Innovative Medicines Initiative is promoting partnerships to 
tackle bottlenecks in drug discovery and development and confront 
areas of healthcare need that are of high priority to society, leading to 
the more efficient discovery and development of better and safer 
medicines for patients. Currently there are more than 40 IMI projects 
covering the whole value chain of pharmaceutical R&D, but with a 
strong focus on drug discovery, as an ideal arena where the PPP 
concept of pre-competitive collaboration can rapidly deliver results 
(for a full list of IMI projects please visit http://www.imi.europa.eu/ 
content/ongoing-projects). 
The starting point of drug discovery is the decision on the 
strategy to take for disease modulation. Since the dawn of the 
genomics era in the 1990s, the main focus of drug discovery has been 
on drug targets, which are typically proteins that appear to have a key 
role in disease pathogenesis. Thus target discovery represents typically 
the first milestone in drug discovery. The recent advances in the 
understanding of the molecular basis of diseases and the completion 
of the Human Genome Project have dramatically expanded the 
number of plausible therapeutic targets for the development of 
innovative drugs. This progress has enabled the development of drugs 
that have revolutionised e.g. cancer treatment (e.g. imatinib, [17]. 
However targets are frequently found to have poor drugability, and 
the current number of novel validated molecular drug targets 
associated with disease pathology is still very limited, making the 
probability of identifying suitable pharmacological modulators 
stubbornly low.  
A key challenge for drug developers is therefore, on the one hand, 
how to most efficiently and successfully choose the best targets from 
the plethora of candidates generated by several large ‘omics’ efforts 
and further develop them into innovative, safe and efficacious drugs. 
The problem is especially severe in complex diseases such for example 
diabetes and its complications, the disorders of the nervous system, 
and cancer.  
On the other hand, for many diseases it may be beneficial to 
target broader pathways or phenotypes instead of single targets. 
Indeed a recent analysis revealed that phenotypic screening has been 
more successful than target-driven screening in delivering first-in-class 
medicines [18], although also this approach has several pitfalls. 
Ideally, an appropriate combination of both approaches should be 
found, to enable researchers to move forward with the best possible 
candidates [18, 19], and create an effective R&D productivity strategy 
delivering innovative products with high-quality information [5].  
In this context the big future wins both for industry and for the 
patients lie more likely in the identification of genes and protein 
molecules associated with disease subtypes and to specific 
pathophysiological events and pathways (molecular phenotyping), or 
related to common causes of drug attrition problems (e.g. 
cardiotoxicity), and in the their successful translation to reliable 
predictions of future events and better estimate of benefit and risk in 
clinical studies. This requires, among other things, significant progress 
on methods and tools for defining molecular mechanisms of action, 
and for better translation of results from research to the clinic [12, 
20]. It is unlikely that any one company working in isolation can 
achieve this goal. A further key issue, slowing down progress, is the 
limited robustness and reproducibility of published academic 
preclinical studies which should pave the way to the development of 
new drugs [21, 22, 23, 24]. Clearly, a concerted action of all 
stakeholders, public and private, is needed to insure success in such 
complex endeavour. 
IMI partnerships are successfully contributing to easing these 
challenges. In this review some examples are provided of outputs of 
IMI projects fostering drug discovery in major disease areas with a 
high impact on the health care burden, as well as developing 
knowledge management tools for prediction of drug safety and 
efficacy. Finally, some details are provided on two most recent 
initiatives with broad potential impact on early drug discovery.  
 
Drug discovery for the treatment of micro- and macrovascular 
complications of diabetes 
 
Diabetes mellitus is a lifelong, incapacitating disease affecting 
multiple organs. The disease is associated with devastating chronic 
complications including coronary heart disease, stroke and peripheral 
vascular disease (macrovascular disease) as well as microvascular 
disorders leading to damage of kidneys (nephropathy) and eyes 
(retinopathy). After 10 years of diabetes, over 70 % of diabetic 
patients have some degree of complications [25]. These complications 
impose an immense burden on the quality of life of the patients. In 
particular diabetic nephropathy (DN) is a complication that develops 
in approximately 25–40 % of diabetic patients and is the leading 
cause of end-stage renal disease (ESRD) in the developed world. 
Currently, 44 % of the new cases of ESRD in the US annually are 
attributable to DN [26]. A better understanding of the causal factors 
of DN and its pathogenesis may lead to new strategies to decrease its 
incidence, pre-emptively treat the disorder, and attenuate morbidity 
and mortality, and as such would be a valuable contribution to global 
public health. One of the objectives of the IMI SUMMIT project 
(http://www.imi-summit.eu) is to identify novel genetic markers 
predicting susceptibility to chronic diabetic complications to provide 
insights into potential targets for biomarker and therapeutics 
development. To this end the SUMMIT consortium has assembled 
and phenotyped the largest genome-wide association study (GWAS) 
database for type 1 diabetes patients with diabetic nephropathy (DN). 
By mining this unique resource of carefully characterised patients, the 
consortium found that several previously reported genetic associations 
with DN in type 1 diabetes could not be replicated in a large, 
homogeneous sample of subjects [27]. In addition SUMMIT 
identified new susceptibility loci associated with kidney disease in 
type 1 diabetes, which represent new signals in the pathogenesis of 
DN [28]. The results of the consortium’s work underscore the need 
to apply stringent statistical thresholds of significance, maximise 
power through meta-analysis of all available data, and seek replication 
in independent samples to obtain data solid enough for supporting 
target drug discovery, as previously indicated by other authors [29] 
and ideally fostered via the PPP collaborative model. Other parts of 
the SUMMIT project are gathering lipidomics, metabolomics and 
other biomarker data which will be linked to phenotypic data of the 
vascular complications of diabetes. Taking advantage of the 
computational tools developed by the consortium [30] and novel 
translatable animal models [31] SUMMIT will develop a network 
model to replace a single target view with a system‐wide perspective of 
diabetes complications to support new strategies for drug developers 
in the area. 
 
Drug discovery for chronic pain 
 
One in five adults suffers from chronic pain. This constitutes a 
major cause of long-term sick leave and forced early retirement, 
placing a great financial burden on both individuals and healthcare 
systems. Despite extensive research programmes by biopharmaceutical 
companies and academia, there remains a need for treatments that are 
more effective and have fewer side-effects [32]. The discovery of new 
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pain mediators amenable to manipulation is likely to yield much 
needed novel therapeutic targets. Approaches to finding pain 
mediators encompass high throughput genetic (GWAS) and 
expression profiling (transcriptomics, proteomics and lipidomics) of 
chronic pain patients and experimental models. A key challenge is that 
pain mechanisms are not always controlled in the same ways in 
preclinical species and in humans [33]. This has often prevented the 
efficient translation of results from the preclinical field to the clinic. 
The EUROPAIN consortium (http://www.imieuropain.org/) has 
established an international team of leading researchers and clinicians 
from both academia and industry to undertake multidisciplinary 
translational research for chronic pain. The consortium is leading a 
major effort for the standardized phenotyping of pain symptoms and 
sensory signs in patients and human surrogate models [34], and 
development of translational animal models and validated outcome 
measures of evoked and spontaneous pain behaviour that more 
accurately depict similar outcome measures used in humans, including 
affective components of pain [35]. These models are rigorously 
standardised via interaction with the industry partners of the 
consortium. By using computational approaches to integrate datasets 
including sensory phenotype as well as the outputs of high 
throughput technologies in humans and rodents, EUROPAIN is 
making progress on deciphering the neurobiology of pain, something 
which has already lead to the identification of an attractive potential 
drug target [36, 37]. 
 
Drug discovery for Autism Spectrum Disorder 
 
Autism spectrum disorder (ASD) is a common neuro-
developmental disorder affecting approximately 1 % of children. 
Autism has life-long consequences with a range of impacts on the 
health, economic well-being, social integration and quality of life of 
individuals with the disorder, and also on their families and 
potentially the rest of society [38](Knapp et al, 2009). A recent 
report [39] estimates that the annual cost to governments for care of 
ASD individuals will increase by 2028 to an estimated $18 billion in 
the US alone. 
Discovering novel treatments for ASD is a challenge. Its aetiology 
and pathology remain largely unknown, the condition shows wide 
clinical diversity, and case identification is still based solely on 
symptomatology. However there has been recent significant progress 
in the understanding of the biology underpinning ASD. This creates 
hope that harnessing these new developments can lead to novel 
treatments driven by the likely biological basis of this condition [40, 
41]. 
The IMI EU-AIMS project (http://www.eu-aims.eu/#) involves 
a novel collaboration between organisations representing affected 
individuals and their families (Autism Speaks), academia and industry 
that for the first time in the world are joining forces to develop the 
infrastructure underpinning new treatments for autism and to develop 
and assess novel treatment approaches for the condition [42]. 
Although this is a very young initiative, which only started 
working in April 2012, the pre-competitive collaborative research 
approach of the project is already bearing fruit. 
Twin and family studies have demonstrated that heritability plays 
a large role in autism. Several risk gene variants have now been 
identified that significantly contribute to ASD susceptibility, many of 
which are linked to synaptic functioning, excitation--inhibition 
balance, and brain connectivity [43, 44]. EU-AIMS partners are 
whole genome sequencing a large number of individuals with autism 
and their parents. The results of this effort will provide an overview 
of the de novo and segregating mutations contributing to the risk of 
autism. The first results of these efforts have already demonstrated a 
role for father’s age in such risk [45]. 
Multiple genetic syndromes include ASD symptoms as part of a 
broader pattern of dysmorphology and medical morbidity [46]. 
Studies of these syndromic forms of ASD have provided significant 
insight in its underlying biology. For example in fragile X syndrome, 
about 25 % of patients meet diagnostic criteria of autism [47]. In 
fragile X, the key defect in synaptic transmission is elevated group I 
metabotropic glutamate receptor-dependent synaptic plasticity 
(mGluR-LTD). EU-AIMS partners have discovered an unexpected 
convergence of synaptic pathophysiology in a non-syndromic form of 
autism with that in fragile X syndrome. Furthermore they have 
demonstrated in a novel knock–out mouse model that the phenotype 
could be rescued, highlighting the possibility of reverting neuronal 
circuit alterations in autism after completion of development [48]. 
The PPP nature of the consortium will now allow the rapid 
incorporation of these new finding into the drug discovery strategy of 
the companies involved, taking advantage as well of the novel 
translational animal models developed by the consortium. 
 
Drug Discovery for cancer 
 
There is a huge cancer burden in Europe. In 2006 there were an 
estimated 3,191,600 new cases of cancer diagnosed, and 1,703,000 
deaths from the disease [49]. While it is widely recognised that major 
advances have been made both in the understanding of the disease and 
also in the treatment of many forms of cancer, a large number of 
anticancer drugs still fail due to a lack of efficacy in late stage trials. 
Improvements in understanding of the underlying biology of cancer 
and the development of new models for target validation is essential 
for supporting the significant advances required to improve the 
quality of cancer drug discovery. Historically in cancer R&D, targets 
have been inappropriately selected or validated due to the use of 
reductionist models which do not represent the complexity of 
tumours in situ, resulting in failure in the clinical setting [50]. 
The PREDECT IMI project (http://www.predect.eu/about/) is 
developing improved in vitro and in vivo models to support target 
identification and target validation in cancer with greater capacity to 
predict outcomes in the human disease. The project approach has 
recently led to a remarkable breakthrough. It is well established that 
estrogens and progesterones are major drivers of breast development 
but also promote carcinogenesis in this organ. ‘Receptor activator of 
nuclear factor κB ligand’ (RANKL) has been identified as a pivotal 
paracrine mediator of progesterone function in mouse mammary 
gland development and mammary carcinogenesis [51, 52]. Whether 
the factor has the same role in humans is of clinical interest because an 
inhibitor for RANKL, denosumab, is already used for the treatment 
of bone disease [53] and might benefit breast cancer patients. 
Taking advantage of a novel ex vivo model to study hormone 
action in the human breast the PREDECT consortium has been able 
to demonstrate that RANKL-mediated hormonal control mechanisms 
are conserved across species [54]. This makes RANKL a potential 
target in breast cancer treatment and prevention, with important 
clinical applications. 
 
Boosting knowledge management for better and earlier 
prediction of drug safety and efficacy 
 
The in silico prediction of biological phenomena on the basis of 
structural information of the drug candidates shows attractive results 
in the case of some molecular pharmacology parameters (e.g., affinities 
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for particular biological targets), in some pharmacokinetics-related 
properties, or for a few toxicological endpoints such as mutagenicity 
[55,56]. Nevertheless, the in silico prediction of most of the 
important in vivo outcomes on the basis of information available in 
early stages of the drug discovery/development is still far from being 
a reality. Early in silico prediction of in vivo toxicological outcomes 
would increase the quality of drug candidates and ensure a lower 
attrition rate during subsequent phases of the drug development 
pipeline. This would also reduce the number of animals to be used in 
in vivo toxicological studies. 
The IMI eTOX project (http://www.etoxproject.eu/) is 
developing innovative methodological strategies and novel software 
tools to better predict the toxicological profiles of new molecular 
entities in early stages of the drug development pipeline. One of the 
pillars of the eTOX project is the integrated use of public and private 
data. With respect to private data, the project is collating information 
from legacy reports obtained in chronic toxicity studies carried out in 
the 13 pharmaceutical companies that participate in the project. In the 
case of public data, eTOX after identification and integration of 
currently available data in the public domain is working in evaluating 
the data quality and its coverage regarding toxicity issues, in order to 
gather and process only data suitable for the building of predictive 
models. The main result of this effort is a large web-based structured 
library containing links to articles of toxicological relevance (data that 
can be used for modeling purposes, computational models, and 
toxicity mechanisms), public databases, standardised vocabularies and 
modeling tools. The library has been made public at the eTOX 
website, where it is updated on a monthly basis, constituting a useful 
resource for the in silico toxicity prediction of novel drug candidates 
[57]. The project is also delivering new computational models for 
early assessment of drug toxicity, suitable for preliminary screening in 
lead discovery, before a compound is physically available. One of 
these models is a multiscale simulation system aiming to produce a 
better cardiotoxicity assessment. The model has been tested in 
predicting the cardiotoxic effect of several compounds, including 
some examples in which classic potassium channel hERG (human 
ether-a-go-go-related gene, K(v)11.1)-based models produce false 
positive or negative results, yielding correct predictions for all of them 
[58]. Another model developed by the project has been shown to be 
useful for the prediction of drug induced nausea and vomiting, a 
common side effect limiting the therapeutic value of many drugs [59] 
Pharmaceutical companies currently expend significant efforts 
integrating the vast amount of data publicly available into internal 
architectures. This is particularly the case with pharmacological data. 
Such problems could be reduced, and R&D efficiency increased, by 
access to a comprehensive database of pharmacological data to help 
initial drug screening stages and limit expensive clinical trial failure. 
The IMI Open PHACTS project (http://www.openphacts.org/) 
integrates multiple publicly-available databases, creating links between 
the data present, allowing access to a vast data resource in a stable and 
rigorous infrastructure. The provenance of all data is easily assessed, 
and traceable back to the parent database, allowing the data quality to 
be evaluated [60]. Furthermore the project has developed several 
applications to query the data for different purposes (PharmaTrek, 
ChemBioNavigator, GARField, Target Dossier, Utopia Documents) 
The Open PHACTS discovery platform has been built to answer 
critical pharmacological questions as defined by academic and 
pharmaceutical industry scientists. In addition to reducing barriers to 
drug discovery within the pharmaceutical industry, the Open 
PHACTS platform allows scientists in academia and smaller 
companies unprecedented access to an integrated database of 
pharmacological information. 
Public Private Partnership approaches for enhancing lead 
discovery and optimisation 
 
IMI has recently launched two novel and challenging initiatives 
with the potential of a broad impact on early drug discovery. These 
are the ‘European Lead Factory’ (ELF) and ‘Kinetics for Drug 
Discovery’ (K4DD) projects. 
High‐throughput screening (HTS) of comprehensive collections 
of chemical compounds has proven to be a major avenue towards the 
identification of novel candidates for further development into lead 
structures and drug candidates, i.e. NCEs. Although pharmaceutical 
companies have built up large libraries of compounds over the years, 
access to these collections has been tightly restricted to in-house use 
by the owners. Meanwhile, the academic community is becoming 
increasingly interested in HTS. Triggered by the NIH roadmap in 
2004 in the United States, this area has recently seen active growth 
also in Europe, e.g. in the EU OPENSCREEN project. Still, public 
compound collections tend to be rather small and expertise in the area 
is scattered across many institutions. As a result, few public drug 
targets have been screened against large, high-quality compound 
libraries. This has hampered efforts to generate promising leads for 
the development of innovative drugs. The IMI-funded European Lead 
Factory (ELF) (http://www.europeanleadfactory.eu/) will provide an 
industry‐like small molecule discovery platform to public investigators 
[61]. Furthermore, as the University of Oxford is a partner in the 
ELF, it will leverage the experience and know-how of the Structural 
Genomics Consortium [62, 63], another important PPP in the field.  
ELF builds on a unique, comprehensive, high‐quality compound 
collection contributed by EFPIA participants, i.e. the Pharma 
Consortium Collection, totalling over 300 000 compounds. To this 
will be added an estimated additional 200 000 novel compounds 
generated by public partner contributions during the project, resulting 
in a unique Joint European Compound Collection with some 500 
000 compounds. This unique collection might then contain more 
three-dimensional molecular structures, as is the case in nature, since 
to date the chemical processes used by the pharmaceutical industry 
have tended to yield planar structures. Screening of these previously-
safeguarded corporate compound libraries against competitors’ targets 
and targets from public sources may result in otherwise inaccessible 
valuable lead structures that could ultimately result in the 
development of novel treatment options for patients.  
There is mounting evidence that the often ignored kinetic aspects 
of the interaction between a small molecule drug and its protein target 
in the body are highly relevant for in vivo efficacy and clinical success 
[64, 65, 66]. It may even be so that lack of understanding of these 
kinetic aspects is one of the main reasons for the high attrition rates in 
drug discovery and development. Therefore, there is a growing need 
for knowledge of the kinetics of binding, as it may play a crucial role 
in drug efficacy and safety. Interestingly, recent overviews showed that 
many approved and successful drugs favour certain kinetic aspects 
[67]. Today, a lot of the expertise and data on binding kinetics is 
scattered across numerous smaller projects, institutions and 
organisations.  
By bringing together these diverse groups, the IMI project 
‘Kinetics for Drug Discovery’ (K4DD) (http://www.k4dd.eu/) is set 
to give a major boost to this important area of drug development. The 
first goal of the K4DD team is to enhance the understanding of 
binding kinetics. Ultimately, the project aims to develop a range of 
robust techniques, methods and models that could be easily 
incorporated into the drug development pathway and enable scientists 
and drug designers worldwide to reliably predict a molecule's kinetic 
properties (its 'kinotype'). This information will allow drug 
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developers to more easily determine the safety and efficacy of a 
molecule. In the long run, this will weed out ineffective or unsafe 
molecules earlier in the drug development process. 
 
Conclusions 
 
Drug discovery key challenges reside in a still incomplete 
understanding of the human diseases and mechanisms investigated, 
followed often by the selection of non-optimal drug molecules for 
further development. Public-private partnerships represent attractive 
means to leverage resources dispersed across industry, academia, and 
voluntary health organisations in order to address its multiple 
challenges, in an era of constrained resources. The reported 
achievements of IMI projects demonstrate that this approach can lead 
to significant advances for the development of innovative drugs.  
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